Abstract:Liquidnet brought in £159 million since its acquisition. The group is now focused on revenue diversification.

TP ICAP, the world‘s biggest inter-deal broker, published its annual financials for 2021, reporting more than 81 percent drop in its profits for the 12 months. It generated £24 million as pre-tax profits last year compared to 2020’s £129 million.
Additionally, the basic earnings per share of the company plunged to 0.7 pence from 15.4 pence in the prior year.
“Our performance naturally reflects the unusually quiet secondary markets that we experienced in 2021, particularly in the first half of the year. However, as market conditions started to improve in the second half, TP ICAP recovered most of the ground and grew overall market share,” said Nicolas Breteau, the CEO of TP ICAP.
Indeed, the revenue of the company showed resilience and came in at £1.86 billion, which is slightly higher than the previous years £1.79 billion. But, Liquidnet turned out to be a successful bet for the company as it brought in £159 million in revenue post-acquisition.
Without adding Liquidnet‘s numbers, TP ICAP’s annual revenue lowered by 1 percent in 2021, which is in line with the guidance provided by the company earlier.
Now, the group is focused on diversifying its revenue stream, bringing 42 percent of its total revenue from non-global broking businesses. Meanwhile, the global broking business of the group declined by 2 percent.
Data and analytics business within Parameta Solutions, which generates a high margin, grew by 10 percent last year.
Cautious on the Outlook
TP ICAP already saw 16 percent in revenue growth until March 11, when compared to the same period of the previous year. In addition, the figure is 4 percent higher without business from Liquidnet.
But, the company is cautious of the market conditions and did not put down any absolute number or range, saying “predicting future market activity is difficult.”
“Market volatility has continued at more elevated levels in 2022, with the return of inflation and geopolitical uncertainty driving higher volumes across many of our markets,” Breteau added.
“While it is too early to judge whether this activity will be sustained, we believe the results of our many actions will show through in improved performance across the group in 2022 and beyond.”


CAPEX.com, a Cyprus-based forex broker, has been receiving flak from its clients all over for its alleged trading practices. These include allegations concerning withdrawal denials to clients, pressuring them into investing more, giving them false promise returns, and causing bonus discrepancies and numerous reported fund scams. With these allegations continuing to grow, it was important for us at WikiFX to highlight before you. This 2026 CAPEX.com review article is aimed at making you aware of trading glitches reported by users. Read on as we share an in-depth guide.

Did Switch Markets lure you into trading with it using a fake bonus scheme? Did your deposit fail to show up in your forex trading account? Were you subject to heavy slippage once the stop-loss triggered? Did you receive a notification from the broker about the sudden deposit seizure? These issues are no longer yours only. Many traders have faced these and vented out on broker review platforms such as WikiFX. In this Switch Markets review article, we have investigated some complaints against the forex broker. Keep reading!

SeptaFX rejected a $2,000 withdrawal and is unregulated; document evidence, stop deposits, and file a complaint now to pursue recovery.

Failed to withdraw funds from RoboForex despite following up with its customer support team numerous times? Did the Belize-based broker close your forex trading account when you requested a fund withdrawal? Did your deposits fail to show up in your trading account? Were you prevented from placing trades due to issues concerning the RoboForex login? These issues have become increasingly common for traders. In this RoboForex review article, we have examined these issues thoroughly to allow you to make an informed decision about the broker. Have a look!